COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: "Intervention group:" Patients with Covid 19 who, in addition to the usual treatment regimens, receive a single dose of infliximab (4 mgr/kg) for 2 hours by infusion. The patient will
Sponsors
Shahre-kord University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Patients with Covid-19 with acute respiratory symptoms between the ages of 18 and 60 who test positive for the SARS-CoV-19 virus by RT-PCR or by CT scan. Lung scan (subpleural lung involvement, bilateral circumference, and more than one area). Saturated oxygen is below 88% Respiratory rate more than 24 times per minute high CRP and D-dimer level, also ferritin above 1000 Lymphopenia with a count of less than 1100
Exclusion criteria
Exclusion criteria: Patients who have a positive test for PPD, HCV, HBS Patients Have a history of neurodegenerative diseases such as multiple sclerosis Patients with heart failure, hypertension, and infections other than Covid 19 infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in paraclinical outcomes. Timepoint: At the beginning of the study (before the intervention) and 7 and 14 days after the start of treatment. Method of measurement: Clinical and laboratory testing.;Blood oxygen levels. Timepoint: At the beginning of the study (before the intervention) and 7 and 14 days after the start of treatment. Method of measurement: Pulse oximeter.;Duration of hospitalization. Timepoint: From the beginning of the study. Method of measurement: Clinical and vital signs. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAkbar Soleymani
Shahre-kord University of Medical Sciences
Outcome results
None listed